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Purpose. To explore the burden of prostate biopsy at the time of its indication, procedure, and pathological report in the prostate
cancer-screening scenario that is neglected and underestimated in the literature. Methods. Prostate biopsy was offered to 47
consecutive patients with prostate-specific antigen (PSA) over 4 ng/dl or suspicious digital rectal examination (DRE) of whom
16 had undergone a biopsy. Comprehensive validated questionnaires at Time 0 (prebiopsy), Time 1 (before diagnosis, 20 days after
biopsy), and Time 2 (after diagnosis, 40 days after biopsy) accessed patients' erectile (IIEF-5) and voiding (IPSS) functions, Beck
scales measured anxiety (BAI), hopelessness (BHS), and depression (BDI), added to the emotional thermometers including five
visual analog scales for distress, anxiety, depression, anger, and need for help.TheMann-Whitney or Friedman tests were obtained
among times and studied variables. Results. Prostate biopsy did not significantly impact patients' erectile and voiding functions
while a higher Beck anxiety index (BAI) was observed at Time 0 (6.89 ± 6.33) compared to Time 1 (4.83 ± 2.87), p=0.0214, and to
Time 2 (4.22 ± 4.98), p=0.0178. At Time 0, patients that experienced a previous biopsy presented higher distress (3.1 ± 3.0 vs. 1.6 ±
2.3), p=0.043, and emotional suffering thermometer scores (2.3 ± 3.3 vs. 0.9 ± 2.4) compared to those undergoing the first biopsy,
p=0.036. At Time 2, patients with positive biopsies compared with those with negative ones showed no significant difference in
outcome scores. The sample power was >90%. Conclusions. To be considered in patients' counseling and care, the current study
supports the hypothesis that the peak burden of prostate biopsy occurs at the time of its indication and might be higher for those
experiencing rebiopsy, significantly impacting patients' psychosocial domains. Trial Approval.This trial is registered under number
NCT03783741.
1. Introduction
Prostate cancer is a very common condition, especially with
aging. Enhancement of life expectancy around the world
consequently promotes an increase of at least 60% in the
diagnosis of prostate cancer. In absolute terms, it is the sixth
most common tumor in the world and the most prevalent in
men, accounting for about 10% of all cancers [1, 2].
The biopsy is considered the best form of histopatho-
logical prostate cancer diagnosis [3]. This diagnosis method
may represent a potent psychological stress factor. In extreme
cases it can increase the risk of negative impacts on recovery
and death from cardiovascular diseases, especially after diag-
nosis [4–6].
Recognizing the real impact of this procedure in the
physical as well as the psychological context is crucial to
provide better support to the patient and minimize side
effects that can hinder posterior treatment.
The aim of this trial is to explore the burden of prostate
biopsy (PBx) at time of its indication, procedure, and patho-
logical report in the prostate cancer-screening scenario that
is neglected and underestimated in the literature.
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Figure 1: Study flowchart.
2. Methods
This is a prospective, longitudinal, and observational study
in which the sexually active patients were evaluated at the
Urology Department of the city of Pauĺınia and submitted to
biopsy guided by transrectal ultrasound after ethics commit-
tee (355.357) and trial (NCT03783741) approvals.
Consecutive patients attended to by a urologist and with
present prostate cancer suspicions (PSA> 4 ng/dL and/or
rectal examination, DRE) [7] were submitted for a PBx.They
were evaluated at three different moments of the biopsy:
(1) Seven days before the biopsy procedure (T0)
(2) 20 days after the biopsy, upon receiving the his-
topathological result, before becoming aware of it (T1)
(3) 40 days after the biopsy, 20 days after being aware of
the test result (T2)
Sixty-one consecutive patients were invited to participate
in the study; 10 of them had no active sexual life and 9
answered the questionnaires only at the first moment and
were excluded; 47 responded at the three times (T0, T1, and
T2) (Figure 1).
Validated instruments were applied: IIEF-5 (erectile func-
tion); IPSS (voiding function); Beck scales (BAI) (anxiety),
BHS (hopelessness), BDI (depression), and emotional ther-
mometers.
The comparison among the moments (T0, T1, and T2)
was performed through the Friedman test (analysis of vari-
ance) for repeatedmeasureswith the variables transformed in
stations. The comparison between patients and variables was
performed using the Mann-Whitney test [8–10]. Multivariate
analysis searched for independent significant variables, the
sample power was calculated, and the level of significance
considered was 5%.
3. Results
Confirmed PCa through biopsies occurred in 32% (n = 15).
The ages varied between 40 and 81 years (mean 62.37 ± 7.97),
and 34% (n = 16) of the patients had already had at least one
previous biopsy performed.
There was no significant impact on erectile and voiding
functions throughout the assessments while a higher Beck
anxiety index (BAI) was observed at Time 0 (6.89 ± 6.33)
compared to Time 1 (4.83 ± 2.87), p=0.0214, and to Time 2
(4.22 ± 4.98), p=0.0178 (Table 1).
At Time 0, patients that experienced a previous biopsy
presented higher distress (3.1 ± 3.0 vs. 1.6 ± 2.3), p=0.043, and
emotional suffering thermometer scores (2.3 ± 3.3 vs. 0.9 ±
2.4) compared to those undergoing the first biopsy, p=0.036
(Table 2).
At Time 2, patients with positive biopsies compared with
those with negative ones showed no significant difference in
outcome scores. The sample power was >90%.
On multivariate analysis BAI was the only independent
variable in the PBx timeline, p=0.0312.
4. Discussion
In the present study, although PBx does not have a significant
short- and medium-term impact on the erectile and voiding
functions, there is interference mainly in anxiety (BAI),
emotional distress, and distress, significantly higher at the
time of biopsy indication, when compared to subsequent
times, even in cases of positive biopsy for PCa.
Thus, it is intriguing to note that although we observed
greater emotional distress and anxiety before the procedure,
these feelings were even greater in the patients submitted to
rebiopsy when compared to those that have never had this
done before and there was no difference between the positive
and negative results for cancer.
These data will allow better patient care in the context of
the early diagnosis of PCa, in order to identify, in addition
to sensitive aspects, also the critical moment (prebiopsy)
to implement psychosocial actions that will minimize the
impact of health interventions such as PBx, culminating in
a better quality of life.
It is important to note that the scope of the study in
question is in line with a current discussion that seeks to
replace the biomedical model with a technical-instrumental
reference of the biosciences by the biopsychosocial model
with a broad and integral view of being and falling ill that
includes the physical, psychological, and social aspects [11].
It is necessary to improve the doctor-patient relation-
ship considering understanding the disease. It is important
to improve communication, increasing flexibility, treating
malaise and disease, respecting diversity, and assessing the
patient's previous historical context, aiming to supply the
needs of the patient to find ways that will allow converging
to the same point aspects between the doctor and the patient
in the same context [12].
It is noteworthy that the psychosocial side effects of
prostatic biopsy have also attracted more attention recently,
especially in relation to emotional issues [13] and although we
have found important statistical differences among the cited
scores, it is quite complex to define the real clinical impact of
interventions such as PBx in the psychosocial context [14].
In the on-screen study we consider the hypothesis that
stress-triggering factors and their organic consequences
occur differently in three moments:
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Table 1: Scores at Times 0, 1, and 2.
Tools T0 T1 T2 p value Sample power
IIEF 15.83 ± 8.52 17.67 ± 8.85 18.06 ± 8.05 ns
IPSS 6.17 ± 5.85 6.22 ± 5.39 4.79 ± 4.81 ns
BAI 6.89 ± 6.33 4.83 ± 2.87 4.22 ± 4.98 0.0178 0.938
BDI 5.61 ± 8.32 4.33 ± 5.71 5.06 ± 6.72 ns
BHS 3.12 ± 3.48 1.94 ± 2.41 3.12 ± 3.14 ns
Table 2: Thermometer scores comparison according to previous biopsy at Time 0.
Tools First biopsy (mean ± SD) >1 biopsy (mean ± SD) p value
Emotional suffering 0.9 ± 2.4 2.3 ± 3.3 0.036
Distress 1.6 ± 2.3 3.1 ± 3.2 0.043
(i) T0: conflicts and concerns arise with the biopsy pro-
cedure and with its result (chance of cancer diagnosis)
(ii) T1: with the proximity of the results of the histopatho-
logical report, concernswere focused on the diagnosis
and the chance of cancer; also 20 days after the biopsy,
residual organic side effects are rare, as previously
described by our group [15]
(iii) T2: the subject is dealing with one of 2 possible
scenarios: positive or negative biopsy for prostate
cancer
The erectile and voiding functions were not significantly
affected when compared the patient's own situations before
PBx. In addition, the patients were more anxious before
the procedure compared to waiting for the diagnosis; Wade
et al. identified that anxiety levels increased 7 days after
the biopsy procedure, dropping at 35 days, maintaining an
increased anxiety only for patients who had a diagnosis of
PCa, suggesting that a broader pre-PBx approachmay reduce
anxiety after the procedure [13].
In a study developed byKlein et al. [16] analyzing effects 1,
4, and 12 weeks after PBx in the erectile, voiding, and quality-
of-life effects, a greater voiding dysfunction was observed
in the first and fourth weeks after PBx, which returned
to normal levels. Regarding erectile function, there was no
significant impact, except for transitory worsening only in
patients with the previous dysfunction. Interestingly, even
without directly asking about anxiety and not having a
prebiopsy evaluation, some patients were anxious after PBx
in the study.
Helfand et al. studying LUTS, ED, and quality of life in
patients submitted to PBx observed significant alterations
only in the erectile function of patients who had confirmed
PCa [17], allowing the interpretation of possible emotional
interference of biopsy positivity as a cause of ED in these
cases.
Zisman et al., who also evaluated pain, anxiety, and erec-
tile function, found 15% of patients with transient EDup to 30
days after PBx, and the highest level of anxiety was detected
in waiting for the histopathological result [18], opposing our
study in which the greatest anxiety was observed before
the biopsy. This fact makes us reflect on the importance of
elucidating doubts and presenting statistical data that will
make the patient more confident and less anxious about the
procedure and its results.
In a study by Chrisofos et al. [19] excluding factors of
comorbidities that would lead to ED as in the present study,
there was also no significant erectile impact after the biopsy.
The present study, of a prospective, observational, and
longitudinal nature, reports the daily practice of a urology
health service. Therefore, the extracted data are applicable
to the daily clinical practice, since an artificial condition for
the research was not prepared. In this context, the mean age
was 62 years and the function scores reveal mild erectile
dysfunction and voiding symptom in this population.
Although the number of patients was relatively small, and
there were patient losses, especially in the last interview, the
power of the sample was adequate for the presented results
(> 90%) and approximately 50 patients were evaluated before
and after the biopsy [20].
The prospective and longitudinal perspective of the study
allows a better definition of causes and effects in the studied
context, minimizing erroneous conclusions when compared
to cross-sectional and retrospective studies.
However, the inclusion of a greater number of subjects
and subsequent evaluations after 40 days of biopsy will allow
the analysis of subgroups of age extremes, erectile and voiding
functions, and long-term data in future studies.
5. Conclusion
In the context of the early diagnosis of PCa, there was no
significant impact on erectile (IIEF-5) and voiding (IPSS)
functions throughout the short- and mid-term evaluations
after PBx. However, there were higher anxiety indexes (Beck
inventory and emotional thermometers), especially at the
time of the indication and in cases with previous biopsy expe-
rience, with no difference between patients with a positive
and negative result for cancer.
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